Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Newell

Showing results (401-410 of 519) with videos related to

Pageof 52
Sort By:
Therapeutic Drug Monitoring|September 1, 1987
Propylene glycol pharmacokinetics and effects after intravenous infusion in humansP A Speth, T B Vree, N F Neilen, et al.
Bioconjugate Chemistry|June 1, 2018
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 InhibitionHonorine Lebraud, Richard A Noble, Nicole Phillips, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767Noel R Monks, David C Blakey, Simon J East, et al.
Biochemical Pharmacology|May 12, 2009
The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2Luke R E Harrison, Christopher J Ottley, D Graham Pearson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 daysA N Hughes, I Rafi, M J Griffin, et al.
CA: a Cancer Journal for Clinicians|November 1, 1991
American Cancer Society guidelines on diet, nutrition, and cancer. The Work Study Group on Diet, Nutrition, and CancerS Weinhouse, D G Bal, R Adamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activityP G Smith, H D Thomas, H C Barlow, et al.
Cancer Research|November 15, 1988
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkagesP E Thorpe, P M Wallace, P P Knowles, et al.
NMR in Biomedicine|May 26, 2017
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRSGilberto S Almeida, Carlo M Bawn, Martin Galler, et al.
British Journal of Cancer|August 1, 1996
The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patientsS Ghazal-Aswad, L Hogarth, A G Hall, et al.
Pageof 52

Showing results (401-410 of 519) with videos related to

Sort By:
Pageof 52
Therapeutic Drug Monitoring|September 1, 1987
Propylene glycol pharmacokinetics and effects after intravenous infusion in humansP A Speth, T B Vree, N F Neilen, et al.
Bioconjugate Chemistry|June 1, 2018
Highly Potent Clickable Probe for Cellular Imaging of MDM2 and Assessing Dynamic Responses to MDM2-p53 InhibitionHonorine Lebraud, Richard A Noble, Nicole Phillips, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767Noel R Monks, David C Blakey, Simon J East, et al.
Biochemical Pharmacology|May 12, 2009
The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2Luke R E Harrison, Christopher J Ottley, D Graham Pearson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 daysA N Hughes, I Rafi, M J Griffin, et al.
CA: a Cancer Journal for Clinicians|November 1, 1991
American Cancer Society guidelines on diet, nutrition, and cancer. The Work Study Group on Diet, Nutrition, and CancerS Weinhouse, D G Bal, R Adamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activityP G Smith, H D Thomas, H C Barlow, et al.
Cancer Research|November 15, 1988
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkagesP E Thorpe, P M Wallace, P P Knowles, et al.
NMR in Biomedicine|May 26, 2017
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRSGilberto S Almeida, Carlo M Bawn, Martin Galler, et al.
British Journal of Cancer|August 1, 1996
The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patientsS Ghazal-Aswad, L Hogarth, A G Hall, et al.
Pageof 52